SINGAPORE – Health technology company Biofourmis has raised $5 million in Series A funding to scale its commercial operations to provide post-acute patient monitoring services and to launch its health analytics platform, biovitals. The company has also partnered with Mayo Clinic to develop a wearable biosensor to predict heart failure. The biovitals platform uses artificial intelligence to integrate and analyze continuous physiology data from clinical grade wearables, and to detect personalized patterns that can predict a patient’s health deterioration. “Our goal is to be an integrated solution and platform that actually reaches the patients, physicians and care teams, payers and hospital providers,” said Kuldeep Singh Rajput, founder and CEO of Biofourmis.
You are here: / / Biofourmis raises $5M, partners with Mayo Clinic